CClinicalTrials.gg
Sign In
CompletedNCT05018741Updated Aug 24, 2021

Prognostic Factors After Liver Transplantation

An observational study in Liver Diseases and Liver Transplant; Complications, sponsored by Changhua Christian Hospital. Completed. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-08-24.

Sponsored by Changhua Christian Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
600
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The study retrospectively reviewed the medical records of patients who received adult liver transplantation in Changhua Christian hospital from 2002 to 2019. We collected their personal data about liver disease, laboratory data about liver function, pre-transplant evaluation and post-transplant outcome. We investigate what prognostic factors may contribute a good survival outcome, and improve our clinical practice.

02

Conditions studied

  • Liver Diseases
  • Liver Transplant; Complications

Browse trials for

Keywords

  • liver transplantation
  • chronic liver disease
  • viral hepatitis
  • alcoholic liver disease
03

In context

Liver Diseases

2,081 studies on the registry are indexed under Liver Diseases; 389 are open to participants now.

This study's enrollment of 600 is above the median of 167 across 681 observational studies indexed under Liver Diseases.

Browse Liver Diseases studies →

Lead sponsor

Changhua Christian Hospital is the lead sponsor of 74 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

Patients with acute liver failure or chronic liver disease due to different etiologies received liver transplantation

Inclusion criteria

  • patients who received adult liver transplantation in Changhua Christian hospital from 2002 to 2019

Exclusion criteria

Exclusion Criteria:

  • patients who did not have suitable donor for liver transplantation
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
600 participants (actual)
Patient registry
No

Groups and cohorts

  • Liver transplant

    Procedure: liver transplantation

Interventions

  • Procedureliver transplantation

    liver transplantation for chronic liver disease or acute liver failure

06

What researchers measure

Primary outcomes

  1. number of participants with morbidity and mortality after surgery

    post-operative complications which requiring interventions, related to organ failure and hospital mortality

    Time frame: upto one month after surgery

Secondary outcomes

  1. long-term survival rate

    1,5 year survival rate

    Time frame: upto 5 years after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Lee SG, Hwang S, Moon DB, Ahn CS, Kim KH, Sung KB, Ko GY, Park KM, Ha TY, Song GW. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl. 2008 Jul;14(7):935-45. doi: 10.1002/lt.21445. PubMed 18581465 ↗
  • Chang Y, Cho Y, Lee JH, Lee YB, Cho EJ, Yu SJ, Sinn DH, Kim BH, Kim SH, Yi NJ, Lee KW, Kim JM, Park JW, Kim YJ, Yoon JH, Joh JW, Suh KS. Comparison of Models for Tumor Recurrence after Liver Transplantation for the Patients with Hepatocellular Carcinoma: A Multicenter Long-Term Follow-Up Study. Cancers (Basel). 2019 Sep 3;11(9):1295. doi: 10.3390/cancers11091295. PubMed 31484287 ↗
  • Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B, Majno P; Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009 Jan;10(1):35-43. doi: 10.1016/S1470-2045(08)70284-5. Epub 2008 Dec 4. PubMed 19058754 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05018741
Lead sponsor
Changhua Christian Hospital
Responsible party
Sponsor
First posted
Aug 24, 2021
Start date
Jan 1, 2002
Primary completion
Dec 31, 2019
Completion
Dec 31, 2019
Last update
Aug 24, 2021

Study contacts

Yao-Li Chen
study chair · Department of General Surgery, Changhua Christian Hospital, Changhua, Taiwan

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Liver Diseases→

Other studies from this sponsor

Changhua Christian Hospital

Start the discussion